Illumina, Genomics England deal to sequence up to 300K people

Illumina and Genomics England announced a new agreement to sequence up to 300,000 genomes over five years.

Under the terms of the agreement, Illumina will deliver up to 300,000 “whole genome equivalents,” with an option to increase the number to 500,000. Initially, samples from NHS patients in England with known rare diseases and cancer types will be eligible for whole-genome sequencing (WGS) to support diagnosis and inform treatment.

The UK NHS Genomic Medicine Service will provide clinical samples, and Genomics England and the UK Life Sciences Strategy will provide samples for research purposes. Illumina Laboratory Services, based in Cambridge, UK, will perform sequencing using the NovaSeq 6000 sequencer.

Population health is not about a one-time research program, but [about] all patients having access to sequencing as a standard of care,” Illumina CEO Francis deSouza said while announcing the agreement at the JP Morgan Healthcare Conference in San Francisco. He added that the “UK is the adoption of genomics at population health level.”


Related presentations

Liked this post?

Share it on your social networks